US 12,071,631 B2
Adenoviral vectors
Ryan Cawood, Oxford (GB); and Weiheng Su, Oxford (GB)
Assigned to Oxford Genetics Limited, Oxford (GB)
Appl. No. 16/634,024
Filed by Oxford Genetics Limited, Oxford (GB)
PCT Filed Jul. 24, 2018, PCT No. PCT/GB2018/052083
§ 371(c)(1), (2) Date Jan. 24, 2020,
PCT Pub. No. WO2019/020992, PCT Pub. Date Jan. 31, 2019.
Claims priority of application No. 1711971 (GB), filed on Jul. 25, 2017; and application No. 1806375 (GB), filed on Apr. 19, 2018.
Prior Publication US 2020/0239909 A1, Jul. 30, 2020
Int. Cl. C12N 15/86 (2006.01)
CPC C12N 15/86 (2013.01) [C12N 2710/10343 (2013.01); C12N 2799/022 (2013.01); C12N 2810/6018 (2013.01); C12N 2830/005 (2013.01)] 16 Claims
OG exemplary drawing
 
1. An adenoviral vector comprising a repressible Major Late Promoter (MLP) and a plurality of adenoviral late genes, wherein the MLP comprises one or more repressor elements which are capable of regulating or controlling transcription of the adenoviral late genes, and wherein the nucleotide sequence of the MLP consists of the nucleotide sequence set forth in SEQ ID NO: 6 or 7.